CAH Stock Recent News

Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago.

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP diluted EPS was $1.65 Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93 Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.85 to $8.00, from $7.75 to $7.90 Company announces the completion of its acquisition of 73% ownership of GI Alliance DUBLIN, Ohio , Jan. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2025 revenues of $55.3 billion, a decrease of 4% from the second quarter of fiscal year 2024. Second quarter revenue increased 16% excluding the impact of the previously communicated large customer contract expiration.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We have narrowed our search to five corporate behemoths set to report earnings results this week. These are: CAH, LOGI, NOW, GLW, ADP.

Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.